This report presents a brief history and background of the MN APCD, including information about APCDs in other states; the role of the MN APCD Workgroup in response to the Minnesota State Legislature’s charge for identifying new and expanded uses for the MN APCD; and the Workgroup’s responses to each of the questions and their implications for next steps in leveraging Minnesota’s APCD. 

This report examines the provision of chronic pain management services in Minnesota from 2010 through 2012. The report includes a description of the volume, geographic distribution, facility type, and provider type/specialty of the rendering provider. 

This report provides a baseline for the volume and associated spending of potentially preventable health care events in Minnesota in 2012.

This report examines chronic disease prevalence and spending for Minnesota residents with health insurance in 2012, using Minnesota’s robust All Payers Claims Database (MN APCD). The report presents overall estimates of prevalence and spending for chronic conditions, considering approximately 125 distinct diseases. It also presents more detailed results for 10 select conditions. Estimates are prepared for the state overall, as well as at the county-level. Chronic Conditions in Minnesota - Supplemental Technical Information (PDF)

This study, commissioned by the 2013 Minnesota Legislature, investigates the feasibility of state-based risk adjustment in Minnesota's individual and small group markets. In the study, the research team assessed the performance of the federal model with Minnesota data and performed statistical and actuarial modeling of a number of scenarios for Minnesota-based risk adjustment, including the effect of reinsurance.

This issue brief provides an overview of pharmaceutical spending and use trends in Minnesota from 2009 to 2013. This first analysis in a series of research initiatives distinguishes between prescription trends in retail pharmacy settings and medical settings (such as physicians’ offices and hospital outpatient clinics). The analysis looks at trends in the number of drug claims, total spending and spending per claim.